Quick Answer
BetterLife Pharma Inc. reported R&D Expense of $424.3 thousand for fiscal year 2025.
BetterLife Pharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $424.3K | -25.7% |
| 2024 | $570.9K | -78.7% |
| 2023 | $2.68M | -50.6% |
| 2022 | $5.42M | +1804.0% |
| 2021 | $284.7K | +346.5% |
| 2020 | $63.8K | -85.2% |
| 2019 | $430.5K | +373.9% |
| 2018 | $90.8K | +56.5% |
| 2012 | $58.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| April 30, 2019 | $59.5K | -45.3% | -8.5% |
| October 31, 2018 | $65.0K | — | -25.1% |
| July 31, 2018 | $86.8K | — | -20.2% |
| April 30, 2018 | $108.8K | — | +716.0% |
| July 31, 2011 | $13.3K | — | -62.1% |
| April 30, 2011 | $35.2K | — | — |
- BetterLife Pharma Inc. showed a decrease of -25.7% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, BetterLife Pharma Inc.’s r&d expense has grown by 631.1% (from $58.0 thousand to $424.3 thousand).
- The most recent figure is from BetterLife Pharma Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on June 2, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: